Close

Horizon Therapeutics (HZNP) Tepezza is Now Underway, Add Stock - Cowen

May 5, 2021 11:30 AM EDT Send to a Friend
Cowen analyst Ken Cacciatore reiterated an Outperform rating and $120.00 price target on Horizon Therapeutics (NASDAQ: HZNP) following Q1 results ...

This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE

Member Login